In the present study, we demonstrated that chronic treatment with the DPPIV inhibitor vildagliptin exerts renoprotective and cardioprotective effects in rats with established HF, reversing cardiac remodeling and improving both LV systolic and diastolic function. The gene discussed is DPP4; the disease is hydrops fetalis.